MGX
Metagenomi, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$1.22-1.61%
Price as of Jul 20, 2026
MGX growth
Metagenomi, Inc. Common Stock growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -50.7%
- EBITDA
- -1.9%
- EBIT
- -5.8%
- EPS
- -9.0%
- Free cash flow
- +16.3%
- Operating cash flow
- +14.5%
Forward estimates
- Revenue
- -55.2%
- EBITDA
- +87.6%
- EPS
- +51.1%
Three-year CAGR
- Revenue
- +13.6%
- EBITDA
- -5.7%
- EBIT
- -8.0%
- Net income
- -12.6%
- EPS
- -12.9%
- Free cash flow
- +20.3%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.